Research programme: histamine H3 receptor antagonists - Eli LillyAlternative Names: THBAZ; TISQ
Latest Information Update: 21 Apr 2009
At a glance
- Originator Eli Lilly
- Mechanism of Action Histamine H3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Schizophrenia
Most Recent Events
- 14 Nov 2005 Preclinical trials in Schizophrenia in USA (unspecified route)